



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Taclonex®

Common Name: Calcipotriene 0.0005% & Betamethasone 0.064% Ointment

PDL Category: Topical - Steroid Combinations

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Dovonex (calcipotriene)	Preferred
Betamethasone dipropionate oint	Preferred

Summary

Indications and Usage: Treatment of psoriasis vulgaris; calcipotriene works by inhibiting epidermal proliferation, decreasing neutophils in psoriatic lesions, and increasing vitamin D receptors in epidermal cells. Betamethasone dipropionate reduces inflammation of the psoriatic plaques.

Dosage Forms: Ointment, 15gm, 30gm, and 60gm

Recommended Dosage: Apply to affected area once daily for up to four weeks (maximum recommended dose: 100gm/week). Application to >30% of body surface area is not recommended.

Common Adverse Drug Reactions: Scaly rash, folliculitis

Contraindications: Hypersensitivity to calcipotriene, butamethasone, or any component of the formulation, calcium metabolism disorders, erythrodermic, exfoliative, and/or pustular psoriasis, viral, fungal, and/or bacterial infection of the skin, vitamin D toxicity.

Manufacturer: Warner Chilcott/LEO Pharma

Analysis: The two active ingredients of this product, calcipotriene (Dovonex®) and betamethasone, are already on the Preferred Drug List separately as preferred products. In addition, several other preferred topical medications exist on the Preferred Drug List that effectively treat psoriasis vulgaris and are more cost effective than Taclonex®.

IME Recommendation:

Preferred Drug

Recommended Drug

Non-Preferred Drug

Non-Recommended Drug

Preferred Drug with Conditions